Several case reports, along with clinical phase I and II studies, have reported that recombinant ACE2 may improve the clinical course of patients with COVID-19 by increasing the degradation of AngII into Ang (1–7), as well as increasing ALM [96,97,98]. The gene discussed is ACE2; the disease is COVID-19.